Skip Nav Destination
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Zhenhua Xu, et al.
Redifferentiation Therapy—Returning to Our Roots in a Post–Kinase Inhibitor World
Maria E. Cabanillas; Naifa L. Busaidy; Steven I. Sherman
Trending - Altmetric
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Last mentioned on Thursday October 6 2022
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Last mentioned on Wednesday October 5 2022
Ewing Sarcoma and Osteosarcoma Have Distinct Immune Signatures and Intercellular Communication Networks
Last mentioned on Tuesday October 4 2022
CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Last mentioned on Wednesday October 5 2022
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Last mentioned on Tuesday October 4 2022
